Category: Seed Funding

  • The startup unicorn myths that quietly mislead founders​

    The startup unicorn myths that quietly mislead founders​

    The 6 unicorn startup myths that quietly mislead founders

    James Church

    WRITEN BY

    James Church

    Author, Investable Entrepreneur

    James is an award-winning business advisor and best-selling author. His clients have raised over £200m in early-stage funding. 

    The startup world loves a good myth.

    Spend enough time in founder circles and you start hearing the same narratives repeated again and again. The technical prodigy who builds a billion-dollar company straight out of university. The startup that wins because it was first to market. The accelerator that unlocks inevitable success.

    These stories are seductive because they simplify success. They make entrepreneurship feel like a formula.

    But the reality is far less tidy.

    Ali Tamaseb, author and venture capitalist, spent four years studying what actually creates billion-dollar startups. His research analysed 30,000 data points from unicorn companies around the world.

    What he found challenges many of the assumptions founders, investors and accelerators have been repeating for years.

    And for many founders, the truth is far more encouraging than the myths.

    The myth of the technical founder advantage

    One belief is that non-technical founders are at a disadvantage. It’s easy to see why this narrative exists. Silicon Valley celebrates engineers and many iconic tech companies were started by developers.

    But the data tells a different story: Just over half of founding CEOs at unicorn startups were non-technical.

    In other words, being a technical founder is not a prerequisite for building a billion-dollar company. Leadership, vision, commercial understanding and execution matter just as much – often more.

    The idea that only technical founders can build great technology companies is simply not supported by the evidence.

    The accelerator success illusion

    Another belief that has become deeply embedded in startup culture is the importance of accelerators. Many founders feel that acceptance into an accelerator is almost a prerequisite for success. The assumption is that these programmes dramatically increase your chances of building a major company.

    Yet the data tells a much less dramatic story.

    According to Tamaseb’s research, 90% of unicorns did not go through an accelerator.

    Of the minority that did, the majority came from one programme – Y Combinator, the global leader in the space. Accelerators can certainly provide valuable networks and early exposure to investors. But the idea that they are a necessary step on the path to unicorn status simply doesn’t hold up.

    The age misconception founders worry about

    Age is another factor that founders often worry about.

    Older founders sometimes assume investors prefer young, highly technical entrepreneurs. Meanwhile, younger founders often feel they lack the experience investors expect.

    The data suggests neither concern is particularly justified.

    The median age of founders in technology startups that became unicorns was 34. In healthcare and biotech, the median age was 42.

    What this really shows is that there is no single “correct” age to build a successful company. Experience matters in some sectors. Fresh thinking matters in others.

    The idea that startup success belongs only to twenty-something founders is more mythology than reality.

    The obsession with being first

    Few ideas are repeated more often in startup circles than the importance of being first to market. Many founders assume that if someone else is already operating in their space, the opportunity has passed.

    But Tamaseb’s research challenges this assumption quite directly.

    85% of unicorn startups had competitors from the moment they were founded. Half were competing with large, established companies. Another 20% entered fragmented markets where a dozen smaller competitors already existed.

    The data suggests that competition is not a barrier to building a major company. In many cases, it simply proves that a market exists.

    Competition is not the problem – differentiation is

    Closely linked to the “first to market” myth is another common belief – that founders should seek markets with little or no competition. In reality, markets without competition often signal something else entirely: limited demand.

    What Tamaseb’s research found instead was the importance of differentiation.

    More than 60% of unicorn startups offered products that were meaningfully differentiated from their competitors.

    That distinction matters. Successful founders are not necessarily the first to enter a market. They are often the ones who deliver a better, clearer, or more compelling solution.

    Sector expertise is not always essential

    Another belief that frequently shapes founder thinking is the idea that deep industry experience is essential before launching a startup. But once again, the data paints a more nuanced picture.

    Only around 30% of founders of unicorn companies in consumer technology had previously worked in that industry. In enterprise and SaaS startups, the number rises slightly to around 40%.

    Healthcare and biotech are the notable exceptions where industry expertise does appear to matter more significantly.

    Across most sectors, however, prior industry experience is far from a universal requirement.

    The skills that actually matter

    If technical backgrounds, accelerators, age and industry expertise are not the decisive factors, what is?

    Tamaseb’s research highlights something much more human.

    The founders who built the most exceptional companies were often those with strong soft skills – the ability to build teams, communicate clearly, sell a vision, and lead organisations through uncertainty.

    These are not glamorous capabilities. They rarely make headlines in startup mythology. But they are fundamental to building and scaling companies.

    The founders who learn the fastest

    One of the most interesting insights from the research is about how exceptional founders behave. The most successful founders were not necessarily those who started with the most knowledge about their sector.

    Instead, they were the ones who learned the fastest.

    • They used their networks.
    • They used their resources.
    • They asked questions relentlessly.

    And over time, they became the people who understood their market better than anyone else.

    Why these myths matter

    Startup myths might sound harmless, but they shape real decisions.

    Founders delay launching companies because they believe they need more technical expertise. Others assume they cannot compete because the market already contains established players. Some believe they need accelerator validation before they can succeed.

    These beliefs quietly discourage capable founders from pursuing opportunities that may well succeed. Yet, the data suggests something very different.

    • There is no single founder profile.
    • No universal startup formula.
    • No guaranteed path to building a billion-dollar business.

    Building companies in the real world

    The reality of entrepreneurship is far messier – and far more open.

    Successful founders come from different backgrounds, different industries, and different stages of life. They enter competitive markets. They learn rapidly. They adapt constantly.

    What ultimately matters is not fitting the myth of a unicorn founder. It’s building something that customers genuinely need, leading a team that can deliver it, and learning faster than the market around you.

    Those qualities rarely make for dramatic startup folklore. But according to the data, they’re far closer to the truth.

  • Great tech doesn’t get funded. Sales do.

    Great tech doesn’t get funded. Sales do.

    Great tech doesn’t get funded. Sales do.

    James Church

    WRITEN BY

    James Church

    Author, Investable Entrepreneur

    James is an award-winning business advisor and best-selling author. His clients have raised over £200m in early-stage funding. 

    There’s a tired joke that no one likes salespeople, and that marketing is the colouring-in department. I hear it all the time. Usually from people who are quietly hoping their product will be so good that sales won’t really matter.

    That hope is why so many startups never raise a funding round.

    If you can’t explain how your business sells, markets, and scales customers, you’re not investable. It doesn’t matter how elegant your technology is. It doesn’t matter how clever the codebase looks in a demo. Capital doesn’t flow towards ideas. It flows towards distribution.

    This is uncomfortable for technical founders. It’s also unavoidable.

    The myth that the best product wins

    There’s a deeply held belief in startup culture that the company with the strongest product will eventually win. That if you just keep building, the market will catch up.

    Investors don’t believe this. They’ve seen too many graveyards full of “brilliant” products that no one ever adopted.

    In reality is that the advantage sits with the company that can create demand predictably. Those with a repeatable sales funnel – a marketing system that fills the pipeline week after week. These things compound faster than product quality ever does.

    I’ve seen this play out very clearly with a client of mine.

    A VC’s cold, rational decision

    My client was pitching to a VC, the only trouble was that VC had a very similar business already in their portfolio – and that company had genuinely market-leading technology. On paper, it was the superior product. But they couldn’t sell it. No consistent pipeline. No repeatable process. Just hope and more funding.

    My client, by contrast, had built a solid sales and marketing system. The product was inferior, but the business knew how to win customers and keep them moving through a funnel. They had incredible conversion rates.

    The VC did something none of us saw coming. They suggested a merger, and not in the direction most founders expect.

    The plan was for the company that could sell (my client) to acquire the company with the better technology. Not the other way around.

    The VC had grown tired of putting money into a business that relied on “one day we’ll crack sales”. Instead, they arranged an acquisition that included the technology and £1 million of cash still sitting in the bank from a previous round.

    From the investor’s perspective, this was the only rational bet. They weren’t prepared to continue backing a company that couldn’t scale users, no matter how good the product was.

    The company that survived wasn’t the one with the best tech. It was the one that knew how to sell.

    What investors actually fear

    Founders often think investors are judging the product. In truth, investors are judging risk.

    After access to capital itself, the biggest killer of startups is an inability to market and sell what’s been built. Investors know this. They’ve lived through it repeatedly.

    A great product with no customers is like owning a supercar with no racetrack. Technically impressive. Commercially pointless.

    This is why sales and marketing competence isn’t a “nice to have” in fundraising conversations. It’s core to how investors decide where to place capital.

    They aren’t asking, “Is this product good?” They’re asking, “Can this team turn attention into revenue at scale?”

    Why sales systems beat talent and charisma

    Many founders assume sales success is about hiring a brilliant salesperson or being personally persuasive in a room. That might work for the first few deals, but investors aren’t backing charisma. They’re backing systems.

    A smart sales and marketing setup has a few defining characteristics:

    • A clear target customer with a defined problem.

    • A repeatable way of reaching that customer.

    • A predictable journey from first touch to closed deal.

    • Data that shows where deals are won and lost.

    When those things exist, revenue becomes something you can forecast rather than hope for. That’s when businesses become fundable.

    In the case of my client, this system meant that once they acquired better technology, they already had people waiting to buy it. The value wasn’t just the pipeline. It was the certainty.

    What this means at different stages

    If you’re pre-launch, this doesn’t mean pretending you have traction. Investors can smell that immediately. What they want is clarity.

    You need to explain, in plain language, how your product will reach customers. Who initiates the buying process. What channels you’ll use. Why those channels make sense for this market, not just because they worked for someone else.

    If you’re post-launch, the bar is higher. You’ll need to show how marketing and sales will deliver the next phase of growth. What happens when current channels saturate. Where marginal cost increases or efficiencies appear.

    In both cases, the question is the same. Do you understand how your innovation turns into adoption?

    The uncomfortable truth

    The VC in my example didn’t back the best product. They backed the best route to market.

    That decision wasn’t emotional. It wasn’t political. It was a simple recognition that execution beats elegance when capital is on the line.

    Today, my client owns technology they didn’t have to build and has a pipeline to monetise it. The technically superior business no longer exists as an independent company.

    Where founders should focus

    The earlier a startup can prove it knows how to sell and market, the more valuable it becomes. Not eventually. Immediately.

    This doesn’t mean chasing vanity metrics or over-engineering funnels. It means being able to explain, with confidence, how growth actually happens in your business. And proving it with pre-orders, letters of intent and waiting lists.

    When you can do that, fundraising conversations change. Investors stop questioning viability and start discussing scale.

    If you’re building something ambitious, ask yourself a simple question. If an investor stripped away your product claims, would your route to market still stand up?

    If the answer is no, that’s where the real work needs to be.

  • Are you building a vitamin or a painkiller?

    Are you building a vitamin or a painkiller?

    Are you building a vitamin or a painkiller?

    James Church

    WRITEN BY

    James Church

    Author, Investable Entrepreneur

    James is an award-winning business advisor and best-selling author. His clients have raised over £200m in early-stage funding. 

    When I speak with founders about their product, most can clearly describe the problem they solve. What’s often missing is how they frame that solution — not just as something that adds value, but as something that genuinely removes pain. The way you frame your proposition determines whether investors see it as essential or optional – as a painkiller, or a vitamin.

    And investors can tell the difference immediately.

    Vitamins vs Painkillers

    A vitamin is a nice-to-have. It makes life a bit better. You might buy it, you might not. If you forget to take it, nothing breaks. A painkiller is the opposite. It solves a problem so painful, you’ll pay for it now. Skip it, and the pain only gets worse.

    It’s the same in business. Products that promise comfort or convenience are vitamins. Products that fix urgent, costly problems are painkillers. Investors know this – and they’re far more likely to back a painkiller.

    Why Investors Favour Painkillers

    Investment is about risk and reward. Painkillers offer both clarity and certainty. They address an immediate pain point, which means customer adoption is faster and willingness to pay is higher. Vitamins, by contrast, rely on persuasion and perfect timing.

    A recent study into what sets unicorns apart found that 70% were positioned as painkillers. Only 30% were vitamins. It’s not hard to see why. A painkiller product doesn’t need to convince the market that a problem exists – the problem is already screaming for attention.

    How to Tell Which One You’re Building

    Ask yourself three questions:

    1. What happens if my product disappears tomorrow? If your customers can carry on as usual, you’ve built a vitamin. If their operations grind to a halt, you’ve built a painkiller.
    2. How urgent is the problem? Vitamins address long-term desires; painkillers address immediate needs. The shorter the time to pain, the stronger your proposition.
    3. Who feels the pain most acutely? The deeper the pain, the easier the sale. Painkillers work best when you know exactly who is hurting and why.

    Real-World Examples

    Take Uber. Before it existed, getting a taxi was unpredictable. You could be stuck in the rain, waving for twenty minutes, unsure if a cab was on its way. Uber’s pitch wasn’t about the app or the GPS – it was about solving that pain: Tap a button, get a ride.

    Or Slack. Endless email chains, constant interruptions, missed messages. Slack didn’t sell itself as a chat tool. It sold relief from chaos: Be less busy.

    These are painkiller propositions. They address pain that’s constant, costly, and obvious.

    Compare that to a vitamin product – something that’s nice to have, like a productivity tracker that helps you reflect at the end of the week. It might be helpful, but no one’s losing sleep without it. That means slow adoption, low urgency, and fragile revenue.

    Why Founders Default to Vitamins

    Many founders build what they want, not what their customers need. They fall in love with ideas, technology, and innovation. They chase trends – AI, blockchain, Web3 – without anchoring in a real customer pain. The result is a product that’s clever, but not critical.

    There’s also comfort in vitamins. They’re easier to sell in conversation. Painkillers require confronting messy, real-world problems. But that’s where value lives. The deeper the pain, the greater the opportunity.

    How to Turn a Vitamin into a Painkiller

    If you suspect your product is a vitamin, all is not lost. You can reposition it. Go back to your customers and find the pain point your product touches. Make that your story. Focus your messaging, your roadmap, and your sales strategy around relieving that pain.

    Instead of saying, “We make teams more efficient,” say, “We eliminate wasted hours that cost your business thousands every week.” Shift from a convenience narrative to a survival narrative.

    Investors respond to that because it connects directly to market demand. It shows you understand what drives urgency – and revenue.

    Pitch the Pain

    Evidence from unicorns shows that painkillers attract faster adoption, stronger customer loyalty, and higher investor confidence. Vitamins can still succeed, but it takes more time, more education, and more luck. If you’re raising capital, make sure your proposition sits on the painkiller side of the line.

    Investors don’t just want to see a product that works. They want to see a market that needs it. And if you can make your customers say, “I can’t live without this,” you won’t have to convince investors of your value – they’ll see it instantly.